ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 447

Rheumatoid Factor Isotypes in Relation to Antibodies Against Citrullinated Peptides in Individuals before Onset of Rheumatoid Arthritis

Mikael Brink1, Monika Hansson2, Linda Mathsson-Alm3, Johan Rönnelid3, Lars Klareskog2 and Solbritt Rantapää-Dahlqvist4, 1Public Health & Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, 2Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, 3Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, 4Public Health & Clinical Medicine/Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Rheumatology, Sweden, Umeå, Sweden

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: ACPA, antibodies and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose

The presence of rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) has been shown to precede the development of rheumatoid arthritis (RA) by several years. The relationships between the separate antibody development of RF and ACPAs are unclear.

Methods

Three isotypes (IgA, IgG and IgM) of RF has been analyzed in samples from 333 pre-symptomatic individuals (contributing with 596 samples), who subsequently developed RA and 495 population controls, all donors to the Biobank of Northern Sweden. The pre-symptomatic samples were collected in median 6.1 (IQR 7.1) years before symptom onset. Cut-offs for RF isotypes were set at 95% specificity using ROC-curves. Data from the RF-isotypes were compared against ten ACPA specificities previously analyzed on a microarray based on the ImmunoCAP ISAC system (Phadia). RF isotypes were analyzed using the EliA on the ImmunoCAP 2500-system (Phadia).

Results

The frequency of RF isotypes in pre-symptomatic individuals were 25.7% for IgA, 17.6% for IgG and 26.7% for IgM, significantly more prevalent compared with controls (p<0.0001). The concentrations for each isotype increased gradually the closer to onset of symptoms the sample was collected.
All three isotypes were associated with smoking (Odds ratio (OR) IgA= 2.5 (95%CI 1.8-3.6), IgG 2.1 (1.4-3.2) and IgM 2.4 (1.7-3.4), respectively) but not with HLA-SE or PTPN22 T-variant. The combinations of each of the RF isotypes with ACPA specificities (a-Enolase (CEP-1/Eno5-21), fibrinogen (Fib)ß36-52, Fibα591, filaggrin (CCP-1/Fil307-324), vimentin ((Vim) 60-75 or Vim2-17) were associated with significantly shorter time to onset of symptoms (p<0.001-0.05). The OR (95%CI) for disease development in IgA, IgG and IgM positive individuals were in combination with Fib36-52, CEP-1 or Fil307-324 further increased from 7.1 (4.5-11.2), 4.5 (2.8-7.3) and 7.4 (4.7-11.7), respectively to OR= 12.5-19.6 for IgA, 7.5-16.2 for IgG and 17.4-20.7 for IgM.

Conclusion

RF isotypes predicted development of RA and in particular using combinations of both ACPAs and RF isotypes the association with disease development was high and the predating time shorter.


Disclosure:

M. Brink,
None;

M. Hansson,
None;

L. Mathsson-Alm,
None;

J. Rönnelid,
None;

L. Klareskog,
None;

S. Rantapää-Dahlqvist,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-factor-isotypes-in-relation-to-antibodies-against-citrullinated-peptides-in-individuals-before-onset-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology